global chronic lymphocytic leukemia therapeutics market 2015-2019

10
Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 www.technavio.co m enquiry@technavi o.com

Upload: technavio

Post on 19-Aug-2015

13 views

Category:

Healthcare


3 download

TRANSCRIPT

Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019

[email protected]

USA – CANADA – UK – CHINA – INDIA

Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019

The report discusses the following in-depth:

• Market Size and Forecast

• Market Segmentation

• Buying Criteria

• Vendor Landscape

• Business Segmentation

• Geographical Segmentation

For more information on theGlobal Chronic Lymphocytic

Leukemia Therapeutics Market 2015-2019,

please mail us [email protected]

USA – CANADA – UK – CHINA – INDIA

Key Trends

Technavio’s Senior Analyst says, “The increase in the patient pool is one of the major factors that will boost the growth of the market during the forecast period. Chronic lymphocytic leukemia is one of the most common types of leukemia reported globally. The recent approval of a few drugs in 2014 to treat the condition is expected to generate substantial revenue for the companies involved. The number of patients is increasing globally, but incidences of the disease are most commonly reported in the US.”

• Chronic lymphocytic leukemia is a malignant condition characterized by increased production of lymphocytes. It has been observed that the cancer first affects B-lymphocytes and then it can spread to other parts of the body. This leukemia is diagnosed mostly at later stages because of the slow buildup of the cancerous cells. During the course of the disease, the malignancy spreads to the spleen, liver, and lymph nodes.

• Technavio's analysts forecast the global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.

• Understanding the key drivers influencing the market

• Understanding the challenges faced by the market

• Activities of various stakeholders involved

• Key focus areas for the vendors

• Major trends that will shape the future of this market

• Vendor landscape and trajectory of the market

• Conclusion

Scope of The Report

A detailed analysis of each market driver, challenge

and trend isavailable in our report:

Global Chronic Lymphocytic Leukemia

Therapeutics Market 2015-2019

USA – CANADA – UK – CHINA – INDIA

USA – CANADA – UK – CHINA – INDIA

Vendors

To understand the vendor landscape and

for a full list of vendors view our report:

Global Chronic Lymphocytic

Leukemia Therapeutics Market 2015-2019

F. Hoffmann-La Roche

Novartis

Teva Pharmaceutical Industries

Roche, a subsidiary of Roche Holding AG, is a healthcare company that undertakes discovery, development, manufacturing, and marketing of innovative diagnostic and therapeutic products and services.

Novartis carries out the research, development, and manufacturing of prescription and generic pharmaceuticals, vaccines, and consumer health products. The company sells these products in various countries that are classified by the company into three reportable regions, the Americas, Europe, and Asia/Africa/Australasia.

Teva Pharmaceutical Industries is an integrated global pharmaceutical company. It undertakes the development, production, and marketing of generic drugs in all treatment categories. It is among the top 10 pharmaceutical companies in the world.

USA – CANADA – UK – CHINA – INDIA

Market Landscape

• The global chronic lymphocytic leukemia therapeutics market is expected to grow at a rapid pace during the forecast period, driven by unmet medical needs and the special provisions granted for orphan drugs.

• In addition, the ICD-10 code designation as well as low advertising costs and growing public awareness are also expected to drive the market during the forecast period.

• However, challenges such as the high cost of therapy, stringent regulatory guidelines, and an unknown disease etiology are expected to hinder the growth of the market.

• Nevertheless, the market is expected to witness certain trends that will foster growth, such as reimbursement policies for the treatment of the disease and regulatory assistance to vendors in emerging nations.

USA – CANADA – UK – CHINA – INDIA

Key Buying Criteria

Parameter Details

Availability Drugs to treat chronic lymphocytic leukemia should be readily available.

EfficacyThe drugs should be able to cure the disease effectively.

Safety The drugs should be safe and cause minimal side effects.

Affordability The drugs should be priced reasonably.

• Growth Forecasts?

• Market Analysis?

• Revenue Forecasts?

• Regional and Country level Analysis?

• Competitive Structure?

• Emerging Trends?

• Vendor Landscape?

• Other?

What Would You Like to Learn From Technavio?

Global Chronic Lymphocytic Leukemia Therapeutics

Market 2015-2019

Let us identify your needs.We would love to hear more!

USA – CANADA – UK – CHINA – INDIA

Our Report Covers: Market Scenarios, Vendor landscape & Industry Road Maps.

You have the Option to Customize Reports & Access Analysts on every Report Purchase.

Purchasing this report?

For media enquiries,please drop us a mail at

[email protected]

We’ll include an hour with our analysts to discuss the report findings.

For free.

USA – CANADA – UK – CHINA – INDIA

Access the Report

USA – CANADA – UK – CHINA – INDIA

India: An Overview

USA – CANADA – UK – CHINA – INDIA

About Us

USA – CANADA – UK – CHINA – INDIA

Thank You!

North America

Chicago, USA

Phone: +1 630 333 9501  

Fax: +1 630 833 2171

Europe

London, United Kingdom

Phone: +44 208 123 1770

Fax: +44 845 280 2825

Asia

Bangalore, India

Phone: +91 934 254 0560

Fax: +91 80 4080 6070

DISCLAIMER

This presentation is intended solely for showcasing Infiniti’s research capabilities. All information contained within this presentation has been randomized and should not be used for any kind of analysis and/or for decision making purpose. All trademarks and copyrights remain the sole ownership of their rightful owners/licensees. In no event shall

Infiniti Research have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with this report, even if Infiniti Research has been advised of the possibility of such damages.

Copyright ©2013 Infiniti Research Limited. All Rights Reserved.

Reproduction without written permission is completely forbidden.

NOT FOR FURTHER DISTRIBUTION